SEATTLE, WA, May 10, 2013 – NorthShore Bio (NSB), developers of digital-biology technologies, announced today that it has been able produce a silicon chip molecular detection platform composed of solid-state "tunable" nanopores that can make direct sequencing faster, simpler and more accessible to researchers, clinicians and field practitioners. The chip's proprietary silicon nanopores can be tuned, or sized, electronically to dimensions that will allow for selective identification of DNA, RNA, small molecules and ion flow.
"NSB's platform is capable of label-free direct electrical detection, making this an extremely integrated and cost-effective solution," said Jonathan DeHart, NSB co-founder and CEO. "Our goal was to create an accurate platform that is truly 'sample-in, answer-out.'"
NSB has been working with scientists at the Institute for Systems Biology to help realize the technology. Dr. Lee Hood, ISB's co-founder and president, believes NSB's platform can help pave the way to new scientific discoveries and therapies.
"NSB's ability to manufacture such a robust platform that can control many variables while eliminating unnecessary steps in the process is the future of molecular detection," Hood said.
Co-founder & Chief Science Officer Dr. Gordon Holt added, "We have uniquely married the domains of electronic measurement and silicon manufacturing with understood chemistries and biology. Tunable nanopores could have a dramatic impact on life sciences research, diagnostics and personalized medicine."
About NorthShore Bio:
NorthShore Bio (NSB) is a life sciences tools and services company that focuses on the development of a direct-to-digital™ silicon nanopore chips for molecular detection, instrumentation appliances, and low-cost genetic sequencing services that will provide a range of tests from simple to data-rich. In late 2011, NSB closed Series A funding with the Oregon Angel Fund and the Institute for Systems Biology. For more information, visit www.northshorebio.com.